Profound Medical Corp (PRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profound Medical Corp (PRN) has a cash flow conversion efficiency ratio of -0.100x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-9.14 Million ≈ $-6.61 Million USD) by net assets (CA$91.06 Million ≈ $65.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Profound Medical Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Profound Medical Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Profound Medical Corp balance sheet liabilities for a breakdown of total debt and financial obligations.
Profound Medical Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profound Medical Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SIM Acquisition Corp. I Class A Ordinary Shares
NASDAQ:SIMA
|
0.000x |
|
IAR Systems Group AB (publ)
ST:IAR-B
|
0.096x |
|
Thoresen Thai Agencies Public Company Limited
BK:TTA-R
|
0.014x |
|
Sunrex Technology Corp
TW:2387
|
0.035x |
|
Kogan.com Ltd
AU:KGN
|
-0.163x |
|
Humedix Co Ltd
KQ:200670
|
0.037x |
|
Metro Mining Limited
F:6ME
|
-0.116x |
|
Luca Mining Corp.
V:LUCA
|
N/A |
Annual Cash Flow Conversion Efficiency for Profound Medical Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Profound Medical Corp from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Profound Medical Corp stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$91.06 Million ≈ $65.87 Million |
CA$-53.39 Million ≈ $-38.62 Million |
-0.586x | -51.03% |
| 2024-12-31 | CA$60.42 Million ≈ $43.71 Million |
CA$-23.45 Million ≈ $-16.97 Million |
-0.388x | +46.47% |
| 2023-12-31 | CA$31.18 Million ≈ $22.56 Million |
CA$-22.61 Million ≈ $-16.36 Million |
-0.725x | -46.16% |
| 2022-12-31 | CA$52.00 Million ≈ $37.62 Million |
CA$-25.80 Million ≈ $-18.66 Million |
-0.496x | -78.87% |
| 2021-12-31 | CA$80.62 Million ≈ $58.32 Million |
CA$-22.36 Million ≈ $-16.17 Million |
-0.277x | -31.24% |
| 2020-12-31 | CA$97.35 Million ≈ $70.42 Million |
CA$-20.57 Million ≈ $-14.88 Million |
-0.211x | +80.31% |
| 2019-12-31 | CA$14.29 Million ≈ $10.34 Million |
CA$-15.33 Million ≈ $-11.09 Million |
-1.073x | -56.19% |
| 2018-12-31 | CA$19.55 Million ≈ $14.14 Million |
CA$-13.43 Million ≈ $-9.72 Million |
-0.687x | +34.59% |
| 2017-12-31 | CA$11.25 Million ≈ $8.13 Million |
CA$-11.81 Million ≈ $-8.55 Million |
-1.050x | -7.46% |
| 2016-12-31 | CA$11.04 Million ≈ $7.98 Million |
CA$-10.79 Million ≈ $-7.81 Million |
-0.977x | -98.96% |
| 2015-12-31 | CA$10.06 Million ≈ $7.28 Million |
CA$-4.94 Million ≈ $-3.58 Million |
-0.491x | +76.65% |
| 2014-12-31 | CA$1.37 Million ≈ $989.71K |
CA$-2.88 Million ≈ $-2.08 Million |
-2.104x | -- |
About Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more